Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.
Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer’s ability to grow, metastasize and acquire resistance to treatments.
We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.
AVB-S6 is comprised of a family of novel, high-affinity, soluble Fc-fusion proteins designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. We have generated preclinical data for AVB-S6 proteins in both solid tumor and hematologic malignancies, including ovarian, renal, pancreatic, and breast cancers, as well as acute myeloid leukemia. Aravive’s current development program benefits from the availability of a complementary serum-based biomarker that it expects will help accelerate drug development and reduce risk by allowing Aravive to select a pharmacologically active dose, to better monitor of therapeutic responses and potentially to better select responder patient populations.
In its recently completed Phase 1 clinical trial with AVB-S6-500, the lead development candidate selected from the AVB-S6 family of proteins, Aravive demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6. In an analysis of the single ascending dose portion of the study, AVB-S6-500 administration resulted in a dose-dependent decrease in measurable, circulating free GAS6 in serum. Importantly, AVB-S6-500 had a favorable safety profile in this first in human study and in preclinical studies. Aravive is poised to initiate the Phase 1b portion of its first Phase 1b/2 clinical trial in patients with platinum resistant ovarian cancer.
Aravive is based in Houston, Texas, where it relocated after receiving a $20 million Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.